The role of clinical pharmacists' intervention on improving the adherence to treatment and clinical outcomes among hemodialysis patients

ISRCTN ISRCTN75517095
DOI https://doi.org/10.1186/ISRCTN75517095
Secondary identifying numbers Grant number 232/2021
Submission date
23/03/2022
Registration date
25/03/2022
Last edited
14/07/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Hemodialysis is a procedure where a dialysis machine and a special filter called an artificial kidney, or a dialyzer, are used to clean your blood.
Following treatment recommendations (adherence) is challenging in hemodialysis (HD) patients, yet it has been found to be extremely crucial in obtaining positive clinical and health outcomes. This study aimed to evaluate the role of clinical pharmacists in enhancing HD patients’ adherence to treatment recommendations and improving clinical outcomes.

Who can participate?
Adult (over 18 years) hemodialysis patients who have been undergoing dialysis for more than three months

What does the study involve?
Patients will receive a monthly educational session, for three months, that covers the disease and its management with recommendations for improving adherence and quality of life. An instructional booklet will be handed to participants in the intervention group as well.

What are the possible benefits and risks of participating?
This study will be beneficial to participants in improving management outcomes. No minimal risk is expected.

Where is the study run from?
Jordan University of Science and Technology

When is the study starting and how long is it expected to run for?
March 2021 to November 2021

Who is funding the study?
This work was supported by the Deanship of Scientific Research at Jordan University of Science and Technology (grant number 232/2021).

Who is the main contact?
Dr Osama Alshogran, oyalshogran@just.edu.jo

Contact information

Dr Osama Alshogran
Principal Investigator

Faculty of Pharmacy/Jordan University of Science and Technology
Irbid
22110
Jordan

ORCiD logoORCID ID 0000-0002-2466-4763
Phone +962 798318927
Email oyalshogran@just.edu.jo

Study information

Study designRandomized open-label clinical trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeQuality of life
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet.
Scientific titleThe role of clinical pharmacist in enhancing hemodialysis patients’ adherence and clinical outcomes: a randomized-controlled study
Study objectivesThe intervention group, which received education from a clinical pharmacist, would be more committed to the recommendations, have fewer complications, and improved clinical outcomes, as compared to the control group (who received standard medical care provided by other health care providers).
Ethics approval(s)Approved 26/04/2021, Institutional review board (IRB) committee at Jordan University of Science and Technology (King Abdullah University 7th Floor - Wing D., Amman - Ramtha highway Irbid Jordan; +962 2 7200600 Ext. (45102); IRB@just.edu.jo), ref: 11/140/2021
Health condition(s) or problem(s) studiedAdherence to treatment in dialysis patients
InterventionUsing stratified sampling based on age and gender, eligible patients were randomly assigned to intervention or control groups.
The intervention group will receive an educational instructional session by a clinical pharmacist that covers recommendations about the disease and its complications, medication information and adherence, common adverse drug events and how to prevent them, the value of adherence to diet and fluid restrictions, the importance of regular follow-up with the medical team and undertaking required laboratory testing, and doing exercise.
The control will receive the usual care.
Follow up is for 3 months.
Intervention typeBehavioural
Primary outcome measureOverall adherence to treatment recommendations assessed using a previously validated ESRD-AQ tool. This was assessed at baseline and after three months of follow up
Secondary outcome measures1. Quality of life measured using KDQOLTM-36 at baseline and after three months of follow up
2. Disease awareness measured using interview with clinical pharmacist at baseline and after three months of follow up
3. Number of emergency or hospital admissions measured using patient records for three months of follow up
4. Biochemical measurements included serum levels of sodium, potassium, urea, creatinine, albumin, hemoglobin level, calcium, phosphorus, and PTH which were obtained from patients' medical records at baseline and after three months of follow up
Overall study start date31/03/2021
Completion date30/11/2021

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants120
Total final enrolment114
Key inclusion criteria1. At least 18 years old
2. Been on continuous HD for at least three months
3. Stable medical condition
Key exclusion criteria1. Mental disease
2. Malignancies
3. Acute illness
4. Terminally ill
5. Under irregular dialysis
Date of first enrolment01/05/2021
Date of final enrolment01/09/2021

Locations

Countries of recruitment

  • Jordan

Study participating centres

King Abdullah University Hospital
Irbid
22110
Jordan
Al-Rashid Hospital
Amman
11937
Jordan
Al-Essra Hospital
Amman
11941
Jordan

Sponsor information

Jordan University of Science and Technology
University/education

Deanship of research
Irbid
22110
Jordan

Phone +962 27201000
Email research@just.edu.jo
Website https://www.just.edu.jo/Deanships/DeanshipofResearch/Pages/Default.aspx#
ROR logo "ROR" https://ror.org/03y8mtb59

Funders

Funder type

University/education

Deanship of Research, Jordan University of Science and Technology
Government organisation / Universities (academic only)
Alternative name(s)
عمادة البحث العلمي جامعة العلوم والتكنولوجيا الأردنية
Location
Jordan

Results and Publications

Intention to publish date01/04/2022
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal
IPD sharing planThe datasets generated during and/or analyzed during the current study are/will be available
upon reasonable request from authors
oyalshogran@just.edu.jo

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 12/07/2022 14/07/2022 Yes No

Editorial Notes

14/07/2022: Publication reference added.
25/03/2022: Trial's existence confirmed by Institutional review board (IRB) committee at Jordan University of Science and Technology